HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

UNC 0638

inhibits lysine methyltransferases G9a and GLP; structure in first source

Also Known As:

UNC-0638; UNC0638

Networked: 14 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - UNC 0638: 14

Experts

1.	Chen, Si-Yun: 1 article (01/2022)
2.	Chu, Pei-Yi: 1 article (01/2022)
3.	Hou, Ming-Feng: 1 article (01/2022)
4.	Lin, Chang-Shen: 1 article (01/2022)
5.	Lin, Hung-Yu: 1 article (01/2022)
6.	Wu, Hsing-Ju: 1 article (01/2022)
7.	Chen, Zhi-Yuan: 1 article (01/2021)
8.	Deng, Huan: 1 article (01/2021)
9.	Fujiwara, Hiroaki: 1 article (01/2021)
10.	Hasegawa, Kiyoshi: 1 article (01/2021)

Related Diseases

1.	Thalassemia 09/01/2020 - "Here, we report the HbF-inducing activity of UNC0638 in erythroid progenitor cells from β-thalassemia/HbE patients. " 09/01/2020 - "Further development of structural analogs of UNC0638 with similar biological effects but improved pharmacokinetic properties may lead to promising therapies and possible clinical application for the treatment of β-thalassemia." 09/01/2020 - "UNC0638 induces high levels of fetal hemoglobin expression in β-thalassemia/HbE erythroid progenitor cells."
2.	Myocardial Infarction 01/01/2020 - "This study tested the hypothesis that combined histone methyltransferase G9a inhibitor (i.e., UNC0638) and erythropoietin (EPO) was superior to either one alone for protecting myocardium from acute myocardial infarction (AMI) damage. "
3.	Neoplasms (Cancer) 02/01/2018 - "Thus, the current data indicates that UNC0638 may be developed as a chemotherapeutic agent to effectively treat metastatic cancers, including TNBC." 10/22/2018 - "Additionally, targeting G9a by siRNA-mediated knockdown or by a selective G9a inhibitor UNC0638 significantly inhibited tumor growth, and dramatically suppressed Wnt signaling pathway in vitro and in vivo. " 04/01/2015 - "UNC0638, a small-molecule inhibitor of histone lysine methyltransferase (HKMT), abolished retention and cooperated with the PARP inhibitor olaparib to block cancer cell growth. " 01/01/2017 - "To address this issue, we characterized by RNA-seq, DNA methylation, and ChIP-seq analyses the epigenetic response of a set of colon, breast, and leukemia cancer cell lines to small-molecule inhibitors against DNA methyltransferases (DAC), histone deacetylases (Depsi), histone demethylases (KDM1A inhibitor S2101), and histone methylases (EHMT2 inhibitor UNC0638 and EZH2 inhibitor GSK343). "
4.	Triple Negative Breast Neoplasms 02/01/2018 - "UNC0638, a G9a inhibitor, suppresses epithelial‑mesenchymal transition‑mediated cellular migration and invasion in triple negative breast cancer."
5.	Virus Diseases (Viral Diseases) 01/01/2016 - "We show that treatment of primary bovine cells with the synthetic EHMT2 inhibitor (UNC0638) either before or shortly after virus infection resulted in a significant increase in transcript levels of bovine IFN-β (boIFN-β; 300-fold) and other IFN-inducible genes, including IFN-stimulated gene 15 (ISG-15), myxovirus resistance 1 (Mx-1), Mx-2, RIG-I, 2',5'-oligoadenylate synthetase 1 (OAS-1), and protein kinase R (PKR). "

Related Drugs and Biologics

1.	Erythropoietin
2.	Histone Methyltransferases
3.	Histone Demethylases
4.	Small Interfering RNA (siRNA)
5.	2',5'-Oligoadenylate Synthetase (2',5' Oligoadenylate Synthetase)
6.	RNA (Ribonucleic Acid)
7.	Histone-Lysine N-Methyltransferase
8.	Protein Kinases (Protein Kinase)
9.	Methyltransferases
10.	Hydrogen Peroxide (Hydroperoxide)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)